231 related articles for article (PubMed ID: 25248682)
1. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Kα inhibitors.
Bruel A; Logé C; Tauzia ML; Ravache M; Le Guevel R; Guillouzo C; Lohier JF; Oliveira Santos JS; Lozach O; Meijer L; Ruchaud S; Bénédetti H; Robert JM
Eur J Med Chem; 2012 Nov; 57():225-33. PubMed ID: 23063566
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and kinase inhibitory activity of novel substituted indigoids.
Beauchard A; Laborie H; Rouillard H; Lozach O; Ferandin Y; Le Guével R; Guguen-Guillouzo C; Meijer L; Besson T; Thiéry V
Bioorg Med Chem; 2009 Sep; 17(17):6257-63. PubMed ID: 19665384
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
[TBL] [Abstract][Full Text] [Related]
7. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.
Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P
Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors.
Putey A; Fournet G; Lozach O; Perrin L; Meijer L; Joseph B
Eur J Med Chem; 2014 Aug; 83():617-29. PubMed ID: 24998602
[TBL] [Abstract][Full Text] [Related]
9. [
Lechner C; Flaßhoff M; Falke H; Preu L; Loaëc N; Meijer L; Knapp S; Chaikuad A; Kunick C
Molecules; 2019 Nov; 24(22):. PubMed ID: 31766108
[TBL] [Abstract][Full Text] [Related]
10. Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.
Yadav RR; Sharma S; Joshi P; Wani A; Vishwakarma RA; Kumar A; Bharate SB
Bioorg Med Chem Lett; 2015 Aug; 25(15):2948-52. PubMed ID: 26048785
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of N,N'-bis(5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl)diamines bearing various linkers and biological evaluation as potential inhibitors of kinases.
Coulibaly WK; Paquin L; Bénie A; Bekro YA; Durieu E; Meijer L; Bazureau JP
Eur J Med Chem; 2012 Dec; 58():581-90. PubMed ID: 23174317
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Development of New 3-(4-Arylmethylamino)butyl-5-arylidene-rhodanines under Microwave Irradiation and Their Effects on Tumor Cell Lines and against Protein Kinases.
Dago CD; Ambeu CN; Coulibaly WK; Békro YA; Mamyrbékova J; Defontaine A; Baratte B; Bach S; Ruchaud S; Guével RL; Ravache M; Corlu A; Bazureau JP
Molecules; 2015 Jul; 20(7):12412-35. PubMed ID: 26184130
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class.
Neagoie C; Vedrenne E; Buron F; Mérour JY; Rosca S; Bourg S; Lozach O; Meijer L; Baldeyrou B; Lansiaux A; Routier S
Eur J Med Chem; 2012 Mar; 49():379-96. PubMed ID: 22305342
[TBL] [Abstract][Full Text] [Related]
15. Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors.
Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
Bioorg Med Chem Lett; 2014 Nov; 24(21):5093-7. PubMed ID: 25282552
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, kinase inhibitory potencies and in vitro antiproliferative activity of isoindigo and 7'-azaisoindigo derivatives substituted by Sonogashira cross-coupling.
Bouchikhi F; Anizon F; Moreau P
Eur J Med Chem; 2009 Jun; 44(6):2705-10. PubMed ID: 19232788
[TBL] [Abstract][Full Text] [Related]
18. Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.
Boulahjar R; Ouach A; Bourg S; Bonnet P; Lozach O; Meijer L; Guguen-Guillouzo C; Le Guevel R; Lazar S; Akssira M; Troin Y; Guillaumet G; Routier S
Eur J Med Chem; 2015 Aug; 101():274-87. PubMed ID: 26142492
[TBL] [Abstract][Full Text] [Related]
19. Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus.
Shaw SJ; Goff DA; Lin N; Singh R; Li W; McLaughlin J; Baltgalvis KA; Payan DG; Kinsella TM
Bioorg Med Chem Lett; 2017 Jun; 27(11):2617-2621. PubMed ID: 28408219
[TBL] [Abstract][Full Text] [Related]
20. Multi-step virtual screening to develop selective DYRK1A inhibitors.
Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
